Related Experiment Video
Updated: Dec 17, 2025
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
20.7K
Association Between FGF-23 Levels and Risk of Fracture in Women With Systemic Sclerosis
Lucia Cantero-Nieto1, Antonio Álvarez-Cienfuegos2, Jose Alberto García-Gómez3
1Department of Emergency, Hospital Santa Ana, Granada, Spain.
Summary
Fibroblast growth factor-23 (FGF-23) levels correlate with fracture risk in women with systemic sclerosis (SSc). FGF-23 may serve as a biomarker for identifying fracture risk in this patient group.
Area of Science:
- Rheumatology
- Endocrinology
- Bone Metabolism
Background:
- Systemic sclerosis (SSc) is associated with increased fracture risk.
- Biomarkers for fracture risk assessment in SSc are needed.
Purpose of the Study:
- To evaluate the association between the Fracture Risk Assessment Tool (FRAX) and serum fibroblast growth factor-23 (FGF-23) levels in women with SSc.
- To compare FGF-23 levels in SSc patients with healthy controls.
Main Methods:
- Cross-sectional study of 62 women with SSc and 62 healthy controls.
- Serum FGF-23 concentration measured by ELISA.
- FRAX score calculated using the online calculator.
Main Results:
- No significant difference in FGF-23 levels between SSc patients and controls (78.2 ± 60.5 vs 80.3 ± 56.3 pg/mL, p=0.662).
- FGF-23 levels showed a positive association with the FRAX index within the SSc group.
Conclusions:
- FGF-23 is associated with the FRAX index in women with SSc.
- FGF-23 may be a promising biomarker for fracture risk detection in SSc patients.
